Given the potential breast cancer subtype-specific effects of miR-7 expression, understanding the role of ER-associated regulation of miR-7 and its downstream targets will underscore the clinical applications of targeting miR-7 as novel therapeutic strategies for ER+ breast cancer patients, as well as TNBC patients. This evidence concerns the gene ESR1 and breast cancer.